Tango Therapeutics updates on PRMT5 program

Oncology-focused biotech company Tango Therapeutics (Nasdaq: TNGX) announced an update on its PRMT5 program.

Tango noted that, based on positive data from the dose escalation and early dose expansion cohorts of the TNG462 Phase I/II clinical trial, it has selected TNG462 to move forward into full development.

TNG908, an MTA-cooperative brain penetrant PRMT5 inhibitor, is clinically active and well-tolerated in non-CNS solid tumors including NSCLC and pancreatic cancer. However, TNG908 did not meet the pharmacokinetic exposure threshold for clinical efficacy in glioblastoma (GBM) in the Phase I/II trial. Thus, the company is introducing TNG456, a next-generation brain penetrant MTA-cooperative PRMT5 inhibitor with enhanced potency and selectivity for the treatment of GBM, NSCLC and selected other solid tumors. TNG908 enrollment is being stopped in order to fully resource TNG462 and TNG456.